Member Info for SneakySimon

I am sure I have heard Colin mention this a couple of times, but he see's the CEO role to deliver turnover and profit and report this at the end of the year - with this being his focus, then makes it a bit clearer why the SP movement isn't really much of a concern.

I don't love that approach - something more upbeat would be better but that's my selfish view as a shareholder (and why it irked me the rampy tweeting that went on around the director sells!)

Charlie - the 'best test in the world' was only approved by MHRA 2 days ago.

Additionally, the clinical results you have shared are AVCT produced ones they have not peer reviewed. They mean as much as Innova's website claim of 99% sensitivity.

Will

If you can name me one of the following, I will bow down to your knowledge
1. Which Spanish hospital was the testing done at?
2. Who authored the Clinical Study

I still wonder why it has not been shared and peer reviewed?

Will, you must be a trading guru - we are so lucky you shar eyour thoughts on LSE for everyone.

Hey Will

You seem a bit sensitive - I was just stating that Clinical Studies always tend to be very successful - always lower when done by a third party

Agreed - ODX is low and AVCT is very high, lets see what happens now we are into the action stage of the LFT rather than the talk stage..........I look forward to AS updates

Innova's own clinical test gave themselves a sensitivity of 99% - it is on their website.

"SneakySimon - Avacta didn't do their own clinical study. You are very boring and wrong!"

Who did it then - it isn't specified on any RNS or publication. Not a single AVCT holder has been able to tell me who did it or even which Spanish hospital ran the study......

I take it all back if you can tell me?

Rocquet - AVCT's test has only been tested by themselves - nothing shared........you don't even know which Spanish hospital.

All companies when they do their own clinical studies 'happen' to come out with amazing results. Look at Innova - theirs came out at 99.8%. Then look at Roche in fact, all the other tests - always very high when they do it themself.

Now look when its independently tests it - the performance is always reduced.

I see AVCT banging on about their gold standard test, but when you compare their own clinical study to other companies clinical studies, it is about on par. So lets see how the third party studies get on first - until then, it is a good test I am sure, but as yet, not verified and not going to be accepted by UKGOV until its been tested and as per the RNS's, their is a stumbling block with the frozen samples (that no-one else has an issue with!).

You now have moved from anticipation stage to now deliver - people will be clambering for all these sales and deals promised - but I suspect that will take time. I also think AVCT's presentation being on the 21st is significant.

I will try to sleep tonight Rocquet - thanks for letting me know.

Interesting - the AVCT test has been rejected at MHRA (StickyStock on Twitter has an email from MHRA confirming it was rejected on the 20th).

rocquet - what are you arguing? AVCT clearly stated in both their RNS in Feb and in the full accounts yesterday that they are unlikely to pass at Porton Down due to the testing method (interestingly the only company to complain about this).

Mologic has not shared anywhere that they have not progressed at Porton Down.

What this tells me is that Omega / Walbrook don't seem to like sharing info - even the non covid business they tell us nothing!!

I missed that Satelite - when were we told it wasn’t Mologic?

Doesn’t the contract for casetting sound a bit odd?

We have had Innova tests for months and these have been recoeved and then pouched etc - so suddenly some are being diverted up to Alva......

I wonder if their is more to it than just rebrading the Innova tests for the government.....

He reminds me of Dave Bramhill at UJO - again, very reserved underselling but thats allowed the SP to be played with something chronic as well as some truly awful communications and placings.

All very similar - always waiting for that great news on the horizon only for them to mess it up some way or another.....

its not failed at all - they have a govt contract for £374m. They have millions of ABC-19 tests produced (and continuing to be manufactured) and two chunky antibody test tenders - and with that will come home use approval.

They have to be quiet right now as everything is confidential - it hasn't been managed well at all, but the fact remains we have a lot of money coming ODX's way very soon.

I honestly think they have had their knuckles rapped - partially the Tesla, but some of the others especially the one about the elections which drove the 15% rise. Silence is probably best when so close to getting contracts (and test to manufacture) confirmed.

Lets face it, with regard to LFT (and potentially ELISA testing) we are going to be all but nationalised!

Maybe the car park changes are for a nw Tesla dealership and the tweet was suggesting we should wait for massive gains and Colin to have the dealership up and running.....

worst case scenario is that the contract is cancelled and we only recieve £50m of the £374.

Two steps:
1. A test must be chosen which we presume must be imminent
2. Then they quarterly are advised how many tests the government wants - thus there is potential that the volume demanded may reduce - I don't suppose that Omega will advise each quarters government volumes

That is why the SP is dropping - the contract was dropped months ago and we seem no clearer as to which test we will be making and thus their is a risk until points 1 & 2 are confirmed.

seriously?!?!?!?

1. I have yet to see any proof he has anything more than a passing friendship
2. None of his 'interviews' have provided anything of substance
3. His tweets show his frustration is the same as ours